Monoclonal antibody S2C4 neutralizes the toxicity of shiga toxin 2 and its variants*

Progress in Biochemistry and Biophysics

Volumn 36, Issue 6, 2009, Pages 736-742

  Jiao, Yong Jun ^a   Zeng, Xiao Yan ^a   Guo, Xi Ling ^a   Shi, Zhi Yang ^a   Feng, Zhen Qing ^b   Wang, Hua ^a  

^a JIANGSU PROVINCIAL CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Monoclonal antibody (mab) s2c4; Neutralization; Shiga toxin 2 (stx2); Stx producing escherichia coli (stec)

Indexed keywords

ESCHERICHIA COLI; MUS;

EID: 70349207205     PISSN: 10003282     EISSN: None     Source Type: Journal    
DOI: 10.3724/SP.J.1206.2008.00415     Document Type: Article

References (28)

1. Tzipori S, Sheoran A, Akiyoshi D, et al. Antibody therapy in the management of shiga toxin-induced hemolytic uremic syndrome. Clin Microbiol Rev, 2004, 17(4): 926-941 (Pubitemid 39372524)
2. Zheng H, Jing H, Wang H, et al. stx2vha is the dominant genotype of Shiga toxin-producing Escherichia coli 0157 : H7 isolated from patients and domestic animals in three regions of China. Microbiol Immunol, 2005, 49(12): 1019-1026
3. Donohue-Rolfe A, Jacewicz M, Keusch G T. Isolation and characterization of functional shiga toxin subunits and renatured holotoxin. Mol Microbiol, 1989, 3(9): 1231-1236 (Pubitemid 19239970)
4. Furutani M, Ito K, Oku Y, et al. Demonstration of RNA N-glycosidase activity of a verotoxin (VT2 variant) produced by Escherichia coli 091 : H21 from patient with the hemolytic uremic syndrome. Microbiol Immunol, 1990, 34(4): 387-392
5. Kozlov Yu V, Kabishev A A, Lukyanov E V, et al. The primary structure of the operons coding for Shigella dysenteriae toxin and temperature phage H30 shiga-like toxin. Gene, 1988, 67(2): 213-221
6. Jackson M P, Newland J W, Holees R K, et al. Nucleotide sequence analysis of structural genes for Shiga-like toxin I encoded by bacteriophage 933J from Escherichia coli. Microb Pathog, 1987, 2 (2): 147-153
7. Tesh V L, Bums J A, Owens J W, et al. Comparison of the relative toxicities of Shiga-like toxins type I and type II for mice. Infect Immun, 1993, 61(8): 3392-3402
8. Wong C S, Jelacic S, Habeeb R L, et al. The risk of the hemolyticuremic syndrome after antibiotic treatment of Escherichia coli 0157 : H7 infections. N Engl J Med, 2000, 342(26): 1930-1936
9. Bitzan M, Klemt M, Steffens R, et al. Differences in verotoxin neutralizing activity of therapeutic immunoglobulins and sera from healthy controls. Infection, 1993, 21(3): 140-145 (Pubitemid 23197139)
10. Mukherjee J, Chios K, Fishwild D, et al. Human Stx2-Specific monoclonal antibodies prevent systemic complications of Escherichia coli ) O157 : H7 infection. Infect Immun, 2002, 70(2): 612-619
11. Nakao H, Kiyokawa N, Fujimoto J, et al. Monoclonal antibody to shiga toxin 2 which blocks receptor binding and neutralizes cytotoxicity. Infect Immun, 1999, 67(11): 5717-5722 (Pubitemid 29508090)
12. Jiao Y, Zeng X, Guo X, et al. Purification and functional characterization of enterohemorrhagic Escherichia coli 0157 : H7 Shiga toxin II. Chin Infect Dis, 2008, 26(4): 217-220
13. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature (London), 1975, 256 (5517): 495-497
14. Xiao G H, Jeffers M, Bellacosa A, et al. Anti-apoptotic signaling by hepatocyte growth factor/Met via the phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase pathways. Proc Natl Acad Sci USA, 2001, 98(1): 247-252
15. Friedrich A W, Bielaszewska M, Zhang W L, et al. Escherichia coli harboring Shiga toxin 2 gene variants: frequency and association with clinical symptoms. J Infect Dis, 2002, 185(1): 74-84
16. Wadolkowski E A, Burns J A, O'Brien A D. Mouse model for colonization and disease caused by enterohemorrhagic Escherichia coli 0157 : H7. Infect Immun, 1990, 58(8): 2438-2445
17. Gannon V P, Teerling C, Masri S A, et al. Molecular cloning and nucleotide sequence of another variant of the Escherichia coli Shiga-like toxin U family. J Gen Microbiol, 1990, 136(6): 1125-1135
18. Ito H, Terai A, Kurazono H, et al. Nishibuchi M. Cloning and nucleotide sequencing of Vero toxin 2 variant genes from Escherichia coli 091 : H21 isolated from a patient with the hemolytic uremic syndrome. Microb Pathog, 1990, 8(1): 47-60
19. Schmitt C K, McKee M L, O ' Brien A D. Two copies of Shiga-like toxin TJ -related genes common in enterohemorrhagic Escherichia coli strains are responsible for the antigenic heterogeneity of the 0157 : H-strain E32511. Infect Immun, 1991, 59(3): 1065-1073
20. Pierard D, Muyldermans G, Moriau L, et al. Identification of new verocytotxin type 2 variant B-subunit genes in human and animal Escherichia coli isolates. J Clin Microbiol, 1998, 36(11): 3317 - -3322
21. Sheoran A S, Chapman S, Singh P, et al. Stx2-specific human monoclonal antibodies protect mice against lethal infection with Escherichia coli expressing Stx2 variants. Infect Immun, 2003, 71 (6): 3125-3130
22. Mizutani S, Nakazono N, Sugino Y. The so-called chromosomal verotoxin genes are actually carried by defective prophages. DNA Res, 1999, 6(2): 141-143 (Pubitemid 129705123)
23. Koudelka A P, Hufnagel L A, Koudelka G B. Purification and characterization of the repressor of the shiga toxin-encoding bacteriophage 933W: DNA binding, gene regulation, and autocleavage. J Bacteriol, 2004, 186(22): 7659-7669
24. Neely M N, Friedman D I. Functional and genetic analysis of regulatory regions of coliphage H-19B: location of Shiga-like toxin and lysis genes suggest a role for phage functions in toxin release. Mol Microbiol, 1998, 28(6): 1255-1267
25. Waldor M K. Bacteriophage biology and bacterial virulence. Trends Microbiol, 1998, 6(8): 295-297
26. Nishikawa K, Matsuoka K, Kita E, et al. A therapeutic agent with oriented carbohydrates for treatment of infections by Shiga toxin-producing Escherichia coli 0157 : H7. Proc Natl Acad Sci USA, 2002, 99(11): 7669-7674
27. Paton A W, Morona R, Patón J C. A new biological agent for treatment of Shiga toxigenic Escherichia coli infections and dysentery in humans. Nat Med, 2000, 6(3): 265-270
28. Yamagami S, Motoki M, Kimura T, et al. Efficacy of postinfection treatment with anti-Shiga toxin (Stx) 2 humanized monoclonal antibody TMA-15 in mice lethally challenged with Stx-producing Escherichia coli. J Infect Dis, 2001, 184(6): 738-742 (Pubitemid 32826425)